Prytime Medical Devices Revenue and Competitors
Estimated Revenue & Valuation
- Prytime Medical Devices's estimated annual revenue is currently $9.2M per year.
- Prytime Medical Devices's estimated revenue per employee is $125,500
- Prytime Medical Devices's total funding is $8.2M.
Employee Data
- Prytime Medical Devices has 73 Employees.
- Prytime Medical Devices grew their employee count by 49% last year.
Prytime Medical Devices's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Commercialization Officer | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | SVP, Quality and Regulatory | Reveal Email/Phone |
4 | VP Engineering | Reveal Email/Phone |
5 | SVP, Research and Product Development | Reveal Email/Phone |
6 | VP, Program Development | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Director Supply Chain | Reveal Email/Phone |
9 | Sr Director Clinical Education | Reveal Email/Phone |
10 | Human Resources Director | Reveal Email/Phone |
Prytime Medical Devices Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $18.6M | 74 | 21% | N/A | N/A |
#2 | $37.7M | 150 | -7% | N/A | N/A |
#3 | $1.4M | 11 | -31% | $5.1M | N/A |
#4 | $49.7M | 198 | 14% | N/A | N/A |
#5 | $1.3M | 10 | 0% | $6.3M | N/A |
#6 | $60.7M | 242 | N/A | N/A | N/A |
#7 | $28.1M | 112 | 8% | N/A | N/A |
#8 | $5.5M | 22 | -19% | N/A | N/A |
#9 | $3M | 12 | -20% | N/A | N/A |
#10 | $10.3M | 41 | N/A | N/A | N/A |
What Is Prytime Medical Devices?
Prytime Medical Devices, Inc., an innovative medical device company, designs, develops and commercializes minimally invasive solutions for hemorrhage control. The company’s flagship product is the ER-REBOA™ Catheter, a 7 Fr compatible balloon catheter designed specifically for rapid, temporary occlusion of large vessels in the emergency and critical care environment during the REBOA (Resuscitative Endovascular Occlusion of the Aorta) procedure. The underlying intellectual property for the ER-REBOA™ Catheter was conceived by experienced military vascular and trauma surgeons, COL. Todd Rasmussen and Dr. Jonathan Eliason, based on lessons learned on the battlefront during combat. The first guidewire free prototype was developed and tested on animals in 2011. Shortly thereafter the company was founded. In October 2015 the ER-REBOA™ Catheter received 510(K) clearance and we began commercializing the device the US market in 2016, followed by the European market. Now approved in Canada as well, use of the device is increasing worldwide, with the total number of hospitals using the ER-REBOA™ Catheter now exceeding 250. The initial market for the device is trauma, with a strong pull developing in adjacent markets including cardiac arrest, postpartum hemorrhage, interventional radiology, perisurgical and pre-hospital in the US and abroad. At Prytime, we are proud to be a part of bringing military medical innovation to the civilian marketplace. We believe that no one should bleed to death; and the sooner you stop bleeding, the better.
keywords:N/A$8.2M
Total Funding
73
Number of Employees
$9.2M
Revenue (est)
49%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Prytime Medical Devices News
Prytime Medical, Inc., a San Antonio, TX-based provider of life saving REBOA products for truncal hemorrhage control. closed a $6m inside financing. The company intends to use the funds for the commercialization of its innovative new products. Led by David Spencer, CEO, Prytime Medical Devices ...
SAN ANTONIO, June 2, 2021 /PRNewswire/ -- Prytime Medical Inc - The REBOA CompanyTM, is a leading innovator and global provider of life saving REBOA products for truncal hemorrhage control. Today, they announced the closing of a $6 million inside financing round to support commercialization of ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 75 | 25% | N/A |
#2 | $7.9M | 79 | 0% | N/A |
#3 | $24.7M | 81 | 8% | N/A |
#4 | $22.5M | 92 | 28% | N/A |
#5 | $7.5M | 116 | 7% | N/A |